grant
Durability of memory T cell responses in melanoma
Organization UNIVERSITY OF MICHIGAN AT ANN ARBORLocation ANN ARBOR, UNITED STATESPosted 7 Apr 2026Deadline 31 Mar 2031
NIHUS FederalResearch GrantFY2026AffectAfter CareAfter-TreatmentAftercareAntigensAntitumor ResponseAutoimmuneBiopsyBloodBlood Reticuloendothelial SystemCancersCell BodyCellsCheckpoint inhibitorClinicClinicalClinical TrialsCutaneousDataDevelopmentDiagnosisDiseaseDisorderEffectivenessExpression SignatureFutureGene Expression ProfileGeneralized GrowthGenerationsGoalsGrowthHumanIFNIFN-GammaIFN-gIFN-γIFNGIFNγImmune InterferonImmune checkpoint inhibitorImmune mediated therapyImmune memoryImmune responseImmunityImmunologic MemoryImmunological MemoryImmunologically Directed TherapyImmunologyImmunomodulationImmunosuppressionImmunosuppression EffectImmunosuppressive EffectImmunotherapyInterferon GammaInterferon Type IIInterferonsInvestigatorsKnowledgeMHC ReceptorMajor Histocompatibility Complex ReceptorMalignant MelanomaMalignant NeoplasmsMalignant Skin NeoplasmMalignant TumorMediatingMediatorMelanomaMelanoma MetastasisMelanoma patientMemoryMetastasisMetastasizeMetastatic LesionMetastatic MassMetastatic MelanomaMetastatic NeoplasmMetastatic TumorMiceMice MammalsModern ManMurineMusNeoplasm MetastasisOutcomeParticipantPatient RecruitmentsPatientsPhenotypePopulationPre-Clinical ModelPreclinical ModelsPrimary NeoplasmPrimary TumorRecurrenceRecurrentResearch PersonnelResearch SpecimenResearchersResectedRoleSecondary NeoplasmSecondary TumorSkinSkin CancerSpecificitySpecimenSurvivorsT cell receptor repertoire sequencingT cell receptor sequencingT cell responseT memory cellT-Cell Antigen ReceptorsT-Cell ReceptorT-Cell SubsetsT-CellsT-LymphocyteT-Lymphocyte SubsetsTCR repertoire sequencingTCR sequencingTCR-seqTCRseqTestingTimeTissue GrowthVitiligoWorkanamnestic reactionanti-tumor immune responseanti-tumor responseautoimmune attackautoimmune destructionautoimmune pathogenesiscancer metastasisdevelopmentalfightinggene expression patterngene expression signaturehigh riskhost responseimmune check point inhibitorimmune microenvironmentimmune modulationimmune regulationimmune suppressionimmune suppressive activityimmune suppressive functionimmune system responseimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimmunogenimmunogenicimmunologic reactivity controlimmunomodulatoryimmunoregulationimmunoregulatoryimmunoresponseimmunosuppressive activityimmunosuppressive functionimmunosuppressive microenvironmentimmunosuppressive responseimmunosuppressive tumor microenvironmentimprovedlFN-Gammamalignancymalignant skin tumormelanocytememory T lymphocytemouse modelmurine modelneoplasm/cancerontogenyparticipant recruitmentpatients suffering from melanomapatients with melanomapost treatmentpre-clinicalpreclinicalprognosticprospectiveresident memory T cellresponders and non-respondersresponders from non-respondersresponders or non-respondersresponders versus non-respondersresponders vs non-respondersresponders/nonrespondersresponseresponse to therapyresponse to treatmentscRNA sequencingscRNA-seqsecondary immune responseside effectsingle cell RNA-seqsingle cell RNAseqsingle cell expression profilingsingle cell transcriptomic profilingsingle-cell RNA sequencingsocial roletherapeutic responsetherapy responsethymus derived lymphocytetissue resident memory T celltranscriptional profiletranscriptional signaturetreatment responsetreatment responsivenesstumortumor cell metastasistumor immune microenvironmenttumor-immune system interactions
Description preview
PROJECT SUMMARY/ABSTRACT
Melanoma is the most lethal type of skin cancer. About 50% of patients with metastatic melanoma have a
meaningful response to treatment with immunotherapy, of which some develop a durable response. Many
patients with the best response to immunotherapy develop immunotherapy-induced melanoma-associated
vitiligo (MAV), an…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click